Investors

About AVROBIO

AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical stage company developing disruptive therapies that have the potential to transform patients’ lives in a single dose.

Stock Quote

Press Releases
August 16, 2019
AVROBIO Appoints Georgette Verdin as Chief Human Resources Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 16, 2019-- AVROBIO, Inc . (NASDAQ: AVRO) (“AVROBIO” or the “Company”), a Phase 2 clinical-stage gene therapy company, today announced the appointment of Georgette Verdin as Chief Human Resources Officer (CHRO). Ms.
August 12, 2019
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 12, 2019-- AVROBIO, Inc. (NASDAQ: AVRO) (“AVROBIO” or the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2018